Concepedia

Ulrich Lücking

UL

Statistics

Publications

26

Citations

2.7K

H-Index

22

Active since

1998

Affiliations

Bayer (Germany)(Current)

Scripps Research Institute

Dana-Farber Cancer Institute

Novartis Institutes for BioMedical Research

Boehringer Ingelheim (Austria)

Ulrich Lücking is an author at Bayer (Germany) specializing in medicinal chemistry, drug discovery, and pharmacology.

Publications per year

1998–2021

26

Publications

26

Neglected sulfur(<scp>vi</scp>) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development

Ulrich Lücking · Organic Chemistry Frontiers · 2019 · 347 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +15

Tuning glycoside reactivity: New tool for efficient oligosaccharide synthesis

Nina Douglas, Steven V. Ley, Ulrich Lücking et al. · Journal of the Chemical Society Perkin Transactions 1 · 1998 · 274 citations

Life Sciences, Chemistry, Carbohydrate Biochemistry +16

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 210 citations

Medicine, Molecular Biology, Oncology +17

Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates

Juan Alberto Sirvent, Ulrich Lücking · ChemMedChem · 2017 · 207 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking, Arne Scholz, Philip Lienau et al. · ChemMedChem · 2017 · 184 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

1–5 of 26